摘要
目的:观察积雪苷外敷并口服联合曲尼司特治疗外伤瘢痕增生的临床疗效及安全性。方法:选取2014年12月-2015年12月邢台市人民医院皮肤科收治的外伤瘢痕增生患者126例,根据用药方案的不同将其分为对照组和观察组,各63例。两组患者均给予曲尼司特胶囊,每次0.1 g,tid;观察组患者在此基础上外敷积雪苷霜软膏适量,每天3~4次,并加服积雪苷片,每次12~24 mg,tid。两组患者均治疗8周。比较两组患者临床疗效、1年内复发率、平均用药时间、症状消失时间、治疗满意度,以及不良反应发生情况。结果:治疗后,观察组患者治疗总有效率(93.65%)明显高于对照组(77.78%),1年内复发率(4.76%)明显低于对照组(15.87%),差异均有统计学意义(P<0.05);观察组患者平均用药时间和症状消失时间明显短于对照组,治疗满意度明显高于对照组,差异均有统计学意义(P<0.05);观察组患者不良反应发生率(6.35%)明显低于对照组(17.46%),差异有统计学意义(P<0.05)。结论:积雪苷外敷并口服联合曲尼司特治疗外伤瘢痕增生疗效显著,可降低患者瘢痕增生复发率,缩短其用药时间和症状消失时间,且安全性较好。
OBJECTIVE： To observe clinical efficacy and safety of asiaticoside topical and oral application combined with tranilast in the treatment of traumatic scar hyperplasia. METHODS： 126 patients with traumatic scar hyperplasia were selected from dermatology department of Xingtai municipal people＇s hospital during Dec. 2014 to Dec. 2015, and then divided into control group and observation group according to treatment plan, with 63 cases in each group. Both groups were given Tranilast capsules, 0.1 g each time, rid; observation group was additionally given moderate Asiaticoside ointment for external use, 3-4 times a day and Asiaticoside tablets orally, 12-24 mg each time, tid. Both groups were treated for 8 weeks. Clinical efficacy, recurrence rate with 1 year, average medication duration, symptom disappearance time and satisfactory degree of treatment were compared between 2 groups as well as the occurrence of ADR. RESULTS： After treatment, total effective rate of observation group （93.65 % ） was significantly higher than that of control group （77.78%） ; recurrence rate with 1 year （4.76%） was significantly lower than control group （15.87%）, with statistical significance （P〈0.05）. Average medication duration and symptom disappearance time of observation group were significantly shorter than those of control group, and satisfactory degree of treatment was significantly higher than control group, with statistical significance （P〈0.05）. The incidence of ADR in observation group （6.35%） was significantly lower than in control group （17.46%）, with statistical significance （P〈0.05）. CONCLUSIONS： Asiaticoside topical and oral application combined with tranilast show significant therapeutic efficacy for traumatic scar hyperplasia, and can reduce the recurrence rate of scar hyperplasia, shorten medication duration and symptom disappearance time with good safety.
出处
《中国药房》
CAS
北大核心
2017年第2期209-211,共3页
China Pharmacy
基金
河北省卫生厅科研基金项目(No.20150174)
关键词
积雪苷
外敷
口服
曲尼司特
外伤瘢痕增生
临床疗效
Asiaticoside
Topical application
Oral application
Tranilast
Traumatic scar hyperplasia
Clinical efficacy
